002038 Stock Overview
A biopharmaceutical company, research, develops, produces, and markets genetic engineering and related drugs in the People’s Republic of China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
My Notes
Capture your thoughts, links and company narrative
Beijing SL Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥8.17 |
| 52 Week High | CN¥10.25 |
| 52 Week Low | CN¥6.16 |
| Beta | 0.33 |
| 1 Month Change | 14.59% |
| 3 Month Change | 22.31% |
| 1 Year Change | -17.06% |
| 3 Year Change | -22.26% |
| 5 Year Change | -37.87% |
| Change since IPO | 684.71% |
Recent News & Updates
Recent updates
Beijing SL Pharmaceutical (SZSE:002038) Is Increasing Its Dividend To CN¥0.15
Jul 02
Beijing SL Pharmaceutical Co., Ltd.'s (SZSE:002038) Popularity With Investors Is Under Threat From Overpricing
Jun 25Why Beijing SL Pharmaceutical's (SZSE:002038) Shaky Earnings Are Just The Beginning Of Its Problems
Apr 30Beijing SL Pharmaceutical Co., Ltd.'s (SZSE:002038) 25% Price Boost Is Out Of Tune With Earnings
Mar 06Shareholder Returns
| 002038 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | 13.0% | -3.0% | -2.1% |
| 1Y | -17.1% | -19.0% | 9.8% |
Return vs Industry: 002038 exceeded the CN Biotechs industry which returned -19% over the past year.
Return vs Market: 002038 underperformed the CN Market which returned 9.8% over the past year.
Price Volatility
| 002038 volatility | |
|---|---|
| 002038 Average Weekly Movement | 6.3% |
| Biotechs Industry Average Movement | 8.9% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in CN Market | 13.0% |
| 10% least volatile stocks in CN Market | 5.8% |
Stable Share Price: 002038 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 002038's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 856 | Mingbo Xu | www.slpharm.com.cn |
Beijing SL Pharmaceutical Co., Ltd., a biopharmaceutical company, research, develops, produces, and markets genetic engineering and related drugs in the People’s Republic of China and internationally. The company’s finished formulations includes temozolomide; arsenic trioxide; lenalidomide capsules; docetaxel; paclitaxel; recombinant human granulocyte colony-stimulating factor; recombinant human interleukin-11; recombinant human interleukin-2; thymopentin; vinorelbine bitartrate; hydroxyl-camptothecine; nimustine hydrochloride; asparaginase; PEG L-asparaginase; calcium foliate; recombinant human basic fibroblast growth factor; liraglutide; insulin aspart 30; insulin aspart 50; insulin aspart; recombinant human follitropin(rh-fsh); ciclosporin; mycophenolate mofetil dispersible; voriconazole; ornidazole; adefovir dipivoxil; levofloxacin hydrochloride; azithromycin; ribavirin; tenofovir disoproxil fumarate; valacylovir hydrochloride; lysozyme; stavudine; tropisetron hydrochloride; granisetron hydrochloride; omeprazole; ademetionine 1,4-butanedisulfonate; glutathione; rivaroxaban; enoxaparin sodium; coenzyme complex; ginkgo biloba extract; simvastatin; telmisartan; naftopidil; nicergoline; zaleplon; cytidine disodium triphosphate; febuxostat; risedronate sodium; loratadine dispersible; somatostatin; octreotide acetate; calcitonin; paracetamol and tramadol hydrochloride; and etodolac. It also offers active pharmaceutical ingredients.
Beijing SL Pharmaceutical Co., Ltd. Fundamentals Summary
| 002038 fundamental statistics | |
|---|---|
| Market cap | CN¥8.20b |
| Earnings (TTM) | CN¥82.39m |
| Revenue (TTM) | CN¥782.29m |
101.9x
P/E Ratio10.7x
P/S RatioIs 002038 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 002038 income statement (TTM) | |
|---|---|
| Revenue | CN¥782.29m |
| Cost of Revenue | CN¥208.31m |
| Gross Profit | CN¥573.99m |
| Other Expenses | CN¥491.60m |
| Earnings | CN¥82.39m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.08 |
| Gross Margin | 73.37% |
| Net Profit Margin | 10.53% |
| Debt/Equity Ratio | 0% |
How did 002038 perform over the long term?
See historical performance and comparisonDividends
1.8%
Current Dividend Yield185%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 11:17 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Beijing SL Pharmaceutical Co., Ltd. is covered by 16 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| YANG QIAO | Changjiang Securities Co. LTD. |
| Shuchang Liu | Changjiang Securities Co. LTD. |
| Jing Qiang | China International Capital Corporation Limited |